Dr. Amy J. Bregar, MD

Dr. Bregar practices at Wentworth-Douglass Hospital in Dover, New Hampshire, part of Mass General Brigham.

Dr. Bregar's NPI, 1851687446, was assigned on June 22, 2011. Dr. Bregar graduated from University of Pittsburgh School of Medicine in 2011. Dr. Bregar holds Massachusetts license 261993.

Dr. Bregar's primary practice is Wentworth-Douglass Hospital, at 789 Central Ave, Dover, NH 03820 in Strafford County. The practice phone is (603) 740-2580.

Dr. Bregar's primary practice is Wentworth-Douglass Hospital in Dover, New Hampshire, part of Mass General Brigham. Dr. Bregar is also affiliated with Massachusetts General Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Bregar to 2 more hospitals, 3 group practices and clinics, 2 medical groups and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bregar practices, 8 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Bregar's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Bregar is licensed in Massachusetts.

CMS data shows 220 Medicare services from Dr. Bregar across 5 procedure codes in 2024, for 144 Medicare patients. Medicare paid $19,729 for them.

CMS counts 144 Medicare patients who saw Dr. Bregar in 2024. The largest group is 65 to 74, with 74 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bregar's median patient age at 71, with 100% women.

In 2024, Dr. Bregar wrote 135 Medicare Part D claims for 35 patients. 70% of them were for generic drugs. CMS names the drug for 50 of them, across 2 drugs with 11 or more claims each, at $801 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

Dr. Bregar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bregar as offering telehealth. CMS counts 19 procedures of removal of the uterus by Dr. Bregar, more than 92% of the clinicians it reports for that procedure.

Dmand AI links 40 papers to Dr. Bregar, published from 2015 to 2025. 2017 was the busiest year, with 8. The most frequent topics are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial and Genital Neoplasms, Female. Dr. Bregar has published most often in Gynecol Oncol. Dr. Bregar's most frequent co-authors are Alexander Melamed, MD, MPH, Annekathryn Goodman, MD and John Orland Schorge, MD.

Dmand AI links Dr. Bregar to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial and Fallopian Tube Diseases.

CMS Open Payments shows 31 general payments to Dr. Bregar from 3 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 77% of the total. Stryker Corporation paid the most, $35,056.

Dr. Bregar graduated from University of Pittsburgh School of Medicine in 2011.